Fundraising Overview - In 2022, the company raised a total of RMB 999,999,990 by issuing 40,404,040 shares at a price of RMB 24.75 per share, with a net amount of RMB 982,949,093.27 after deducting issuance costs [1] - As of June 30, 2025, the balance of the fundraising account was RMB 40,524,489.26, with specific amounts held in various banks [2] Fund Management - The company has established a fundraising management system to ensure the proper use of raised funds, adhering to principles of regulation, safety, efficiency, and transparency [1] - A tripartite supervision agreement was signed with several banks to manage the fundraising account, ensuring compliance with regulatory requirements [2] Fund Utilization - As of June 30, 2025, the company has used RMB 30,000,000 of idle funds to temporarily supplement working capital, with a usage period not exceeding 12 months [3] - The company has not used any excess funds for permanent working capital or to repay bank loans during the reporting period [4] Project Status - The company has not changed the use of fundraising projects, and there are no significant issues in the management and disclosure of fundraising [4] - The company plans to extend the completion date for several projects, including the expansion of automation equipment in the new energy sector and the upgrade of automation equipment in the consumer electronics sector, to December 31, 2026, due to market conditions and strategic adjustments [5]

证券代码：002544 证券简称：普天科技 公告编号：2025-035 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 中电科普天科技股份有限公司（简称"本公司"或"公司"）第七届董事 会第九次会议于 2025 年 8 月 25 日（星期一）下午以通讯表决方式召开，会议通 知和会议资料于 2025 年 8 月 14 日以专人送达或电子邮件方式向全体董事、监事、 高级管理人员发出。本次会议应参与表决董事 9 名，实际参与表决董事 9 名。会 议符合《中华人民共和国公司法》等相关法律、行政法规、部门规章、规范性文 件和本公司《公司章程》的规定，会议合法有效。 中电科普天科技股份有限公司 第七届董事会第九次会议决议公告 二、董事会会议审议情况 经与会董事认真审议，以记名投票表决方式通过了以下议案： 公司董事、高级管理人员保证《公司 2025 年半年度报告》内容真实、准确、 完整，不存在任何虚假记载、误导性陈述或重大遗漏。 本议案已经公司董事会审计委员会审议通过。 《2025 年半年度报告全文》（公告编号 2025-037）及《2025 年半年 ...

| 证券代码：688013 证券简称：天臣医疗 公告编号：2025-048 | | | | | --- | --- | --- | --- | | 天臣国际医疗科技股份有限公司 | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 | | | | | 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | 根据中国证券监督管理委员会《上市公司募集资金监管规则》和《上海证券 | | | | | 交易所科创板上市公司自律监管指引第 1 号——规范运作》及相关格式指引等有 | | | | | 关规定，天臣国际医疗科技股份有限公司（以下简称"天臣医疗"、"公司"或"本 | | | | | 公司"）董事会编制了 2025 年半年度募集资金存放与实际使用情况专项报告。 | | | | | 一、募集资金基本情况 | | | | | （一）实际募集资金金额及到账时间 | | | | | 天臣医疗经中国证券监督管理委员会《关于同意天臣国际医疗科技股份有限 | | | | | 公司首次公开发行股票注册的批复》（证监许可[2020]2020 号）核准，公司向社 | ...

国联民生证券承销保荐有限公司（以下简称"保荐机构"）作为碧兴物联科 技（深圳）股份有限公司（以下简称"碧兴物联"、"公司"）首次公开发行股 票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海 证券交易所科创板上市公司自律监管指引第1号——规范运作》和《上市公司募集 资金监管规则》等法律法规有关规定，对碧兴物联使用自有资金支付募投项目所 需资金并以募集资金等额置换的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意碧兴物联科技（深圳）股份有限公司 首次公开发行股票注册的批复》（证监许可[2023]1009号）同意注册，公司首次公 开发行人民币普通股（A股）19,630,000.00股，每股发行价格36.12元，募集资金总 额为人民币709,035,600.00元，扣除不含税发行费用人民币85,592,015.58元，实际募 集资金净额为人民币623,443,584.42元，该募集资金已于2023年8月4日到账。上述 募集资金到位情况已经立信会计师事务所（特殊普通合伙）审验，并出具了信会 师报字[2023]第ZL10015号验资报告。 二、募集资金投资项目 ...

国泰海通证券股份有限公司 关于浙江华远汽车科技股份有限公司 首次公开发行股票募投项目结项并将节余募集资金永久补 流及注销募集资金专户事项的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为浙江 华远汽车科技股份有限公司（以下简称"浙江华远"、"公司"或"发行人"）首次公 开发行股票并在创业板上市的持续督导保荐机构，根据《证券发行上市保荐业务 管理办法》《上市公司募集资金监管规则》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等相关法律、法规和规范性文件的规定，对浙江华远首次公开发行股票募投 项目结项并将节余募集资金永久补流及注销募集资金专户事项进行了审慎核查， 具体核查情况如下： 一、首次公开发行股票募集资金的基本情况 经中国证券监督管理委员会《关于同意浙江华远汽车科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1973 号）同意，公司首次公开 发行人民币普通股（A 股）6,379.4118 万股，每股面值为人民币 1.00 元，每股发 行价格为人民币 4.92 元，募集资金总额为人民币 313, ...

Group 1 - The board of directors of Jiangsu Hengxing New Material Technology Co., Ltd. held its 13th meeting on August 26, 2025, with all 7 directors participating and voting [1][2]. - The board approved the "2025 Half-Year Report and Summary," which is available on the Shanghai Stock Exchange website [1][2]. - The board also approved the "Special Report on the Storage and Actual Use of Raised Funds for the First Half of 2025," confirming compliance with relevant regulations and accurate disclosure of fund usage [2][3]. Group 2 - The board agreed to use up to RMB 490 million of temporarily idle raised funds for cash management, ensuring that this does not affect the normal investment plans or harm the interests of the company and its shareholders [2][3].

证券代码：688479 证券简称：友车科技 公告编号：2025-026 用友汽车信息科技（上海）股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 用友汽车信息科技（上海）股份有限公司（以下简称"公司"）第四届监事 会第五次会议于 2025 年 8 月 26 日以通讯表决方式在公司会议室召开，会议通知 于 2025 年 8 月 19 日以电子邮件方式送达全体监事。本次会议应到监事 3 人，实 到监事 3 人，会议由监事会主席郭新平先生召集并主持。会议的召集和召开程序 符合《中华人民共和国公司法》和《用友汽车信息科技（上海）股份有限公司章 程》等相关规定，会议形成的决议合法、有效。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《2025 年半年度报告》及《2025 年半年度报告摘要》。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 （二）审议通过《关于 2025 年半年度募集资金存放与实际使用情况的专项 报告的议案》 经审议，监事会认为公司 2 ...

Meeting Overview - The second session of the Supervisory Board of Jiangsu Hengxing New Material Technology Co., Ltd. was held on August 26, 2025, combining in-person and remote attendance [1] - The meeting was chaired by Mr. Yao Yunsong, and all procedures complied with relevant laws, regulations, and the company's articles of association [1] Supervisory Board Resolutions Half-Year Report - The Supervisory Board approved the 2025 Half-Year Report, confirming that it meets regulatory requirements and accurately reflects the company's operational and financial status [1][2] - The report's preparation and review processes adhered to legal and internal management regulations [1] Fund Usage Report - The Supervisory Board approved the Special Report on the storage and actual use of raised funds for the first half of 2025, stating it accurately reflects the situation as of June 30, 2025, with no violations in fund usage [2] Cash Management Proposal - The company plans to use up to RMB 490 million of temporarily idle raised funds for cash management, which is expected to enhance fund efficiency without affecting project construction or normal operations [2][3]

Summary of Key Points Core Viewpoint The report provides a detailed account of the fundraising activities and the management of the raised funds by the company, highlighting the total amount raised, the allocation of funds, and the compliance with regulatory requirements. Group 1: Fundraising Overview - The company raised a total of RMB 3,450,000,000.00 through the issuance of convertible bonds, with a net amount of RMB 3,429,570,000.00 after deducting issuance costs [1][2] - As of June 30, 2025, the total amount of funds utilized was RMB 3,020,581,226.28, with a remaining balance of RMB 0 [1][2] Group 2: Fund Management - The company established a fundraising management system in compliance with relevant laws and regulations to ensure the proper use and management of the raised funds [1][2] - A special account was opened for the management of the raised funds, and agreements were signed with relevant banks and sponsors to oversee the fund's usage [1][2] Group 3: Fund Usage and Allocation - The company utilized RMB 358,131,282.05 to replace self-raised funds that were previously invested in projects before the issuance of the convertible bonds [3][4] - The remaining funds from completed projects were permanently allocated to supplement working capital, totaling RMB 12,445.16 million [3][4] Group 4: Project Status and Adjustments - The company reported that all fundraising projects have been completed, and there were no changes to the fundraising projects during the reporting period [3][4] - The company adjusted the investment scale for the Huizhou plant electronic product project and allocated the surplus funds to the construction of a new factory in Mexico [2][3]

Summary of Key Points Core Viewpoint Ningbo Meinuo Pharmaceutical Co., Ltd. has provided a special report on the management and actual use of raised funds for the first half of 2025, detailing the amount raised, its allocation, and the management of these funds in compliance with regulatory requirements. Group 1: Fundraising Overview - The total amount raised through the issuance of convertible bonds was RMB 512,697,629.67, with all funds received by January 20, 2021 [1] - As of June 30, 2025, the net amount of raised funds was RMB 512,697,629.67, with RMB 120,013,509.22 allocated to supplement working capital [1][2] - The company earned RMB 2,447,966.77 in interest income from deposits, while RMB 2,018,894,525.00 was temporarily idle in financial products [1][3] Group 2: Fund Usage and Management - The company has implemented a dedicated account storage system for raised funds, ensuring compliance with relevant laws and regulations [1] - As of June 30, 2025, the total balance in dedicated accounts was RMB 20,183,440.32, with specific allocations for high-end formulation projects and raw material projects [1][2] - The high-end formulation project is expected to be completed by July 2025, with ongoing construction and planning [1][3] Group 3: Cash Management of Idle Funds - The company has approved the use of idle raised funds for cash management, with a maximum daily balance of RMB 25,000,000 allowed for investment in liquid and capital-preserving products [2] - As of June 30, 2025, the total amount used for cash management was RMB 29,000,000, generating a return of RMB 390,400 [2][3] - The company has not experienced any significant changes in the feasibility of its projects or the need to temporarily supplement working capital with idle funds [2][3]